Catalyst
Slingshot members are tracking this event:
FDA Approves DURECT's (DRRX) NDA for PERSERIS (risperidone), formerly known as RBP-7000, Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DRRX |
|
|
||||
Additional Information
On September 26, 2017, DURECT entered into a patent purchase agreement whereby DURECT has assigned to Indivior UK Limited, an affiliate of Indivior PLC, certain patents that may provide further intellectual property protection for PERSERIS. In consideration for such assignment, Indivior made an upfront non-refundable payment to DURECT of $12.5 million.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 30, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Schizophrenia, Rbp-7000, Persersis, Risperidone
